Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

N.Y. jury urged to hold drugmakers liable for U.S. opioid crisis

Published 06/29/2021, 06:14 AM
Updated 06/29/2021, 05:41 PM
© Reuters. FILE PHOTO: Tablets of the opioid-based Hydrocodone at a pharmacy in Portsmouth, Ohio, June 21, 2017.  REUTERS/Bryan Woolston

By Brendan Pierson

NEW YORK (Reuters) -Teva Pharmaceutical Industries, Endo International (NASDAQ:ENDP) and Abbvie Inc's Allergan (NYSE:AGN) misleadingly marketed opioid drugs as having a low addiction risk, a lawyer for a New York county told jurors on Tuesday, urging them to hold the companies liable.

Jayne Conroy, representing Suffolk County, also said that the drugmakers and the nation's largest drug distributors - AmerisourceBergen (NYSE:ABC) Corp, Cardinal Health Inc (NYSE:CAH) and McKesson Corp (NYSE:MCK) - failed to report suspicious opioid orders as required.

The U.S. Centers for Disease Control and Prevention has said nearly 500,000 people died from opioid overdoses in the United States from 1999 to 2019.

"Profits soared, and our communities were devastated," Conroy said.

"Manufacturers and distributors control the valve to stop the flood of opioids," she added. "They have their hands on this."

The defendants, whose lawyers are expected to deliver opening statements beginning on Wednesday, have denied any wrongdoing.

Suffolk is suing the companies alongside neighboring Nassau County and New York Attorney General Letitia James. The trial in Central Islip, New York, marks the first time governments' claims over the nationwide opioid crisis have gone before a jury.

Hunter Shkolnik, representing Nassau County, and John Oleske, representing the state, used their opening statements to give the jury a preview of their case, expected to include expert witnesses and internal communications from the companies.

Johnson & Johnson (NYSE:JNJ), which had been a defendant, announced on Saturday it would pay $263 million to settle and avoid the trial. The healthcare company said the amount represented what it would pay New York under a $26 billion nationwide opioid settlement it proposed last year along with the three distributors that has not been finalized.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

New York and the counties claim that drug companies deceptively promoted opioids as safe, and that distributors ignored red flags that massive amounts of the painkillers were being diverted to illegal channels.

More than 3,000 lawsuits have been filed in the United States against drugmakers, distributors and pharmacies over the opioid epidemic, mostly by city, county and tribal governments.

Non-jury trials are already underway in cases brought against the four drugmakers by several counties in California, and against the three distributors by a city and county in West Virginia.

The New York counties had also sued pharmacy operators Walmart (NYSE:WMT) Inc, Rite Aid (NYSE:RAD) Corp, CVS Health Corp (NYSE:CVS) and Walgreens Boots Alliance (NASDAQ:WBA) Inc, but they were dropped from the trial. CVS said it had settled, without disclosing terms, while Walmart and Rite Aid declined to comment. Walgreens could not be reached for comment.

Latest comments

Sue whoever has $ and ignore the doctors and patients who actually are guilty.
No real threat to the drug companies: nothing that a few million$ in campaign contributions to the right politicos won't cure.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.